Survival of women with ovarian carcinomas and borderline tumors is not affected by estrogen and progesterone receptor status

Autor(es)

Sallum, Luis Felipe ^[1] ; Sarian, Luis Otavio ^[1] ; De Angelo Andrade, Liliana Lucci ^[2] ; Vassallo, Jose ^{[3, 4, 5]} ; Soares, Fernando Augusto ^[3] ; Pinto, Glauce Aparecida ^[5] ; Ferreira, Patricia Andreia ^[6] ; Derchain, Sophie ^[1]

Afiliação do(s) autor(es)

^[1] State Univ Campinas UNICAMP, Dept Obstet & Gynecol, Sao Paulo - Brazil

^[2] State Univ Campinas UNICAMP, Fac Med Sci, Dept Pathol, Sao Paulo - Brazil

^[3] Hosp Canc AC Camargo, Fundacao Antonio Prudente Sao Paulo, Dept Pathol, Sao Paulo - Brazil

^[4] State Univ Campinas UNICAMP, CIPED, Dept Pathol, Lab Investigat & Mol Pathol, Campinas, SP - Brazil

^[5] State Univ Campinas UNICAMP, CAISM, Lab Expt Pathol, Sao Paulo - Brazil

^[6] State Univ Campinas UNICAMP, Fac Med Sci, Sao Paulo - Brazil

• Tipo de documento: Artigo Científico
• Fonte: JOURNAL OF GYNECOLOGIC ONCOLOGY; v. 24, n. 2, p. 167-176, APR 2013.
• Citações Web of Science: 6

Resumo

Objective: To examine the patterns of estrogen receptor (ER) and progesterone receptor (PR) expression in borderline ovarian tumors (BOTs) and ovarian carcinomas. We also assessed the disease-free survival (DFS) and overall survival (OS) in women with ovarian carcinoma, in relation to ER and/or PR expression. Methods: We examined ER/PR expression in 38 BOTs and 172 ovarian carcinomas removed from patients treated at the State University of Campinas-UNICAMP (Brazil), from 1993 to 2008 and followed for up to 60 months using tissue microarray-based immunohistochemistry. Results: Twenty-eight (73.7%) mucinous and 10 (26.3%) serous BOTs were included. Ovarian carcinomas consisted mainly of 79 (46.0%) serous, 44 (25.5%) mucinous, 17 (9.8%) endometrioid, 10 (5.8%) clear-cell types. There was no significant difference of the ER/PR expression between BOT and ovarian carcinoma (p=0.55 for ER alone, 0.90 for PR alone, and 0.12 for combined expression). The level of ER/PR expression in BOTs was significantly higher in serous than in mucinous tumors (p<0.01). In carcinomas, ER/PR was higher in serous tumors than in mucinous (p<0.01) and clear cell tumors (p=0.02), and higher in endometrioid tumors than in mucinous tumors (p<0.01). DES was affected neither by the clinical characteristics nor by combined steroid receptor status. OS was found to be significantly worse (p<0.01) only in women with stages II-IV tumors and those with residual disease after surgery (p<0.01). Conclusion: Overall, serous and endometrioid tumors were predominantly ER/PR positive, whereas mucinous and clear-cell tumors were preponderantly ER/PR negative. DFS and OS were not affected by ER/PR expression. (AU)

• Processo FAPESP: 09/18306-3 - Correlação entre a expressão da p53, Ki67, WT1, ²-catenina e receptores hormonais em relação aos aspectos morfológicos e clínicos dos tumores epiteliais borderline e invasivos de ovário
• Beneficiário: Patricia Andreia Rodrigues Ferreira
• Modalidade de apoio: Bolsas no Brasil - Iniciação Científica